---
title: "Humira (adalimumab) in rheumatoid arthritis: Safety questions"
description: "Safety questions on Humira (adalimumab) in rheumatoid arthritis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings, Side effects, and Safety evidence. Questions: Can Humira cause a lupus-like syndrome? What are Humira's most common side effects in rheumatoid arthritis? How often do Humira side effects lead to stopping treatment in RA? What less common serious Humira side effects occurred in RA trials? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Humira (adalimumab) in rheumatoid arthritis: Safety questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Humira](https://www.rxabbvie.com/pdf/humira.pdf)

Safety questions that apply to every indication of Humira are on [Humira (adalimumab), all indications: Safety](https://www.evicenter.com/medical-information/humira/safety).

## Warnings

<a id="humira-lupus-autoimmunity"></a>

### Can Humira cause a lupus-like syndrome?

> “Treatment with HUMIRA may result in the formation of autoantibodies and, rarely, in the 
> development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions (6.1, 
> 6.3)]. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or 
> autoimmune hepatitis following treatment with HUMIRA, discontinue treatment and evaluate 
> the patient.”

Source: [HUMIRA: Prescribing information, page 13, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=13)

> “In the rheumatoid arthritis controlled trials, 12% of subjects treated with HUMIRA and 7% of 
> placebo-treated subjects that had negative baseline ANA titers developed positive titers at week 
> 24. Two subjects out of 3046 treated with HUMIRA developed clinical signs suggestive of new-
> onset lupus-like syndrome. The subjects improved following discontinuation of therapy. No 
> subjects developed lupus nephritis or central nervous system symptoms. The impact of long-term 
> treatment with HUMIRA on the development of autoimmune diseases is unknown.”

Source: [HUMIRA: Prescribing information, page 15, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=15)

## Side effects

<a id="humira-ra-common-side-effects"></a>

### What are Humira's most common side effects in rheumatoid arthritis?

> “Most common adverse reactions (>10%) are: infections (e.g. upper 
> respiratory, sinusitis), injection site reactions, headache and rash. (6.1)”

Source: [HUMIRA: Prescribing information, page 2, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=2)

> “Table 1 summarizes reactions reported at a rate of at least 5% in subjects treated with HUMIRA 
> 40 mg every other week compared to placebo and with an incidence higher than placebo. In 
> Study RA-III, the types and frequencies of adverse reactions in the second year open-label 
> extension were similar to those observed in the one-year double-blind portion.  
>
> Table 1. Adverse Reactions Reported by ≥5% of Subjects Treated with HUMIRA During 
> Placebo-Controlled Period of Pooled RA Studies (Studies RA-I, RA-II, RA-III, and RA-IV)  
>
> HUMIRA 
> 40 mg subcutaneous 
> Every Other Week  
> Placebo 
>
> (N=705) 
> (N=690) 
> Adverse Reaction (Preferred Term)”

Source: [HUMIRA: Prescribing information, page 16, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=16)

> “Respiratory 
>
>
>      Upper respiratory infection 
> 17% 
> 13% 
>      Sinusitis 
> 11% 
> 9% 
>      Flu syndrome 
> 7% 
> 6% 
> Gastrointestinal 
>
>
>      Nausea 
> 9% 
> 8% 
>      Abdominal pain 
> 7% 
> 4% 
> Laboratory Tests* 
>
>
>      Laboratory test abnormal 
> 8% 
> 7% 
>      Hypercholesterolemia 
> 6% 
> 4% 
>      Hyperlipidemia 
> 7% 
> 5% 
>      Hematuria 
> 5% 
> 4% 
>      Alkaline phosphatase increased 
> 5% 
> 3% 
> Other 
>
>
>      Headache 
> 12% 
> 8% 
>      Rash 
> 12% 
> 6% 
>      Accidental injury 
> 10% 
> 8% 
>      Injection site reaction ** 
> 8% 
> 1% 
>      Back pain 
> 6% 
> 4% 
>      Urinary tract infection 
> 8% 
> 5% 
>      Hypertension 
> 5% 
> 3% 
> *  Laboratory test abnormalities were reported as adverse reactions in European trials 
> ** Does not include injection site erythema, itching, hemorrhage, pain or swelling”

Source: [HUMIRA: Prescribing information, page 17, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=17)

Note: Table 1 continues from page 16 to page 17 of the Prescribing Information. Its columns are HUMIRA 40 mg every other week (N=705) and placebo (N=690), in that order.

<a id="humira-ra-discontinuation"></a>

### How often do Humira side effects lead to stopping treatment in RA?

> “The proportion of subjects who discontinued treatment due to adverse reactions during the 
> double-blind, placebo-controlled portion of studies in subjects with RA (i.e., Studies RA-I, RA-
> II, RA-III and RA-IV) was 7% for subjects taking HUMIRA and 4% for placebo-treated 
> subjects. The most common adverse reactions leading to discontinuation of HUMIRA in these 
> RA studies were clinical flare reaction (0.7%), rash (0.3%) and pneumonia (0.3%).”

Source: [HUMIRA: Prescribing information, page 14, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=14)

<a id="humira-ra-less-common-side-effects"></a>

### What less common serious Humira side effects occurred in RA trials?

> “Less Common Adverse Reactions in Rheumatoid Arthritis Clinical Studies 
> Other infrequent serious adverse reactions that do not appear in the Warnings and Precautions or 
> Adverse Reaction sections that occurred at an incidence of less than 5% in HUMIRA-treated 
> subjects in RA studies (RA-I, RA-II, RA-III, and RA-IV) were:  
> Body As A Whole: Pain in extremity, pelvic pain, surgery, thorax pain  
> Cardiovascular System: Arrhythmia, atrial fibrillation, chest pain, coronary artery disorder, heart 
> arrest, hypertensive encephalopathy, myocardial infarct, palpitation, pericardial effusion, 
> pericarditis, syncope, tachycardia  
> Digestive System: Cholecystitis, cholelithiasis, esophagitis, gastroenteritis, gastrointestinal 
> hemorrhage, hepatic necrosis, vomiting  
> Endocrine System: Parathyroid disorder  
> Hemic And Lymphatic System: Agranulocytosis, polycythemia”

Source: [HUMIRA: Prescribing information, page 17, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=17)

> “Metabolic And Nutritional Disorders: Dehydration, healing abnormal, ketosis, paraproteinemia, 
> peripheral edema  
> Musculo-Skeletal System: Arthritis, bone disorder, bone fracture (not spontaneous), bone 
> necrosis, joint disorder, muscle cramps, myasthenia, pyogenic arthritis, synovitis, tendon 
> disorder  
> Neoplasia: Adenoma  
> Nervous System: Confusion, paresthesia, subdural hematoma, tremor  
> Respiratory System: Asthma, bronchospasm, dyspnea, lung function decreased, pleural effusion  
> Special Senses: Cataract  
> Thrombosis: Thrombosis leg  
> Urogenital System: Cystitis, kidney calculus, menstrual disorder”

Source: [HUMIRA: Prescribing information, page 18, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=18)

## Safety

<a id="humira-ra-antibodies"></a>

### Do antibodies to Humira affect how well it works in RA?

> “Rheumatoid Arthritis and Psoriatic Arthritis: Subjects in Studies RA-I, RA-II, and RA-III were 
> tested at multiple time points for antibodies to adalimumab using the ELISA during the 6- to 12-
> month period. No apparent correlation of antibody development to adverse reactions was 
> observed. With monotherapy, subjects receiving every other week dosing may develop 
> antibodies more frequently than those receiving weekly dosing. In subjects receiving the 
> recommended dosage of 40 mg every other week as monotherapy, the ACR 20 response was 
> lower among antibody-positive subjects than among antibody-negative subjects. The long-term 
> immunogenicity of HUMIRA is unknown.”

Source: [HUMIRA: Prescribing information, page 22, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=22)

> “Rheumatoid Arthritis<sup>a</sup> 
>
> 6 to 12 
> months 
> 5% (58/1062)”

Source: [HUMIRA: Prescribing information, page 21, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=21)

> “<sup>a</sup> In patients receiving concomitant methotrexate (MTX), the incidence of anti-adalimumab antibody was 
> 1% compared to 12% with HUMIRA monotherapy”

Source: [HUMIRA: Prescribing information, page 21, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=21)

Note: The second passage is the rheumatoid arthritis row of Table 2 (study duration, then incidence by ELISA). The third passage is footnote a of Table 2, which applies to that row.

## Safety evidence

<a id="humira-premier-safety"></a>

### What serious Humira side effects occurred over 2 years in early RA (PREMIER)?

Applies to: Adults with early moderate to severe rheumatoid arthritis (less than 3 years' duration) who had not received methotrexate (PREMIER, Study RA-V)

> “Safety data: 2-year RCT<sup>2,3</sup>
>
> Adverse reaction rates observed in clinical trials may not predict the rates observed in a broader patient population in clinical practice.
>
> Overall Year 1 and Year 2 (events per 100 patient-years)
>  	HUMIRA + MTX
> (n=268) PYs=482	HUMIRA
> monotherapy
> (n=274) PYs=435	MTX
> monotherapy
> (n=257) PYs=429
> SERIOUS INFECTION	2.9	0.7	1.6
> MALIGNANCY<sup>a</sup>	0.4	0.9	0.9
> ACTIVE TUBERCULOSIS	0.2	0	0
> LYMPHOMA	0	0	0.2
>
> <sup>a</sup>Excluding non-melanoma skin cancer and lymphoma”

Source: [HUMIRA: HUMIRA® (adalimumab) for Rheumatoid Arthritis (RA), captured 2026-11-13](https://www.humirapro.com/rheumatoid-arthritis#:~:text=Safety%20data%3A%202%2Dyear,non%2Dmelanoma%20skin%20cancer%20and%20lymphoma)

## Related pages
- [Medical information: Humira (adalimumab): Rheumatoid arthritis](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis)
- [Indication](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis/access-and-coverage)
